Discounted Cash Flow
Belite BIO Inc. ADR
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2020 | — | $-5.8m | $-4.4m | — | $-0.65 |
| 2021 | — | $-9.7m (-68.0%) | $-7.5m (-69.9%) | — | $-1.01 (-55.4%) |
| 2022 | $7.0k | $-12.6m (-30.9%) | $-11.9m (-57.0%) | -180685.7% | $-0.63 (37.6%) |
| 2023 | $49.0k (600.0%) | $-31.6m (-150.1%) | $-29.9m (-152.3%) | -64555.1% (64.3%) | $-1.19 (-88.9%) |
| 2024 | $3.7m (7485.7%) | $-36.1m (-14.3%) | $-29.4m (1.8%) | -972.4% (98.5%) | $-1.18 (0.8%) |
| 2025 | $6.6m (78.6%) | $-77.6m (-114.7%) | $-37.1m (-26.3%) | -1169.2% (-20.2%) | $-2.31 (-95.8%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.